Drug Trial Radar · NCT07245771
Phase 1/2a Study to Evaluate the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics and Effect on Body Weight of RN3161 as Monotherapy and in Combination With Tirzepatide in Adults With Overweight and Obesity
Last checked: Nov 19, 2026Latest source record: Nov 24, 2025 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Recruiting
Enrollment
104
Planned (sponsor's estimate)
Start
Nov 4, 2025
Primary completion
Feb 15, 2027
Study completion Aug 15, 2027
Sponsor
- Lead sponsor
- Ikaria Bioscience Pty LtdIndustry
- Sponsor type
- Industry
- Collaborators
- Shanghai Rona Therapeutics Co., Ltd.
- First posted
- Nov 24, 2025
Design
- Study type
- Interventional
- Phase
- Phase 1 / Phase 2
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Quadruple (participant, care provider, investigator, outcomes assessor)
- Primary purpose
- Treatment
- FDA-regulated drug
- No
- Who can join
- All sexes, from 18 years, up to 65 years
- Healthy volunteers
- Yes
Summary
As written by the sponsor on the registry.
Study to assess the safety, pharmacokinetics (the amount of study drug or any of its breakdown products in your body) and pharmacodynamics (how the study drug affects your body) of RN3161 alone (healthy volunteers) and RN3161 with tirzepatide (overweight and obese subjects)
Conditions
- Obesity &Amp; Overweight
Interventions
RN3161Drug
Investigational Product
Placebo ControlDrug
0.9% normal saline SC injection
TirzepatideDrug
In Part 3; randomized to either RN3161 + tirzepatide or placebo + tirzepatide
Primary outcomes
What the sponsor says the trial is designed to measure.
- Blood PressureTime frame: 180 Days
- ECG PR intervalTime frame: 180 days
- Physical ExaminationTime frame: 180 days
- Blood Chemistry LaboratoryTime frame: 180 days
- Adverse EventsTime frame: 180 days
- Heart RateTime frame: 180 days
- ECG QRS ComplexTime frame: 180 days
- ECG QT intervalTime frame: 180 days
- Blood Hematology LaboratoryTime frame: 180 days
- Blood Coagulation LaboratoryTime frame: 180 days
Locations
1 site in 1 country. Site status is shown where the registry gives one.
Nucleus Network Pty Ltd
Melbourne, Victoria, Australia · Recruiting
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.